Study of COYA 302 for the Treatment of ALS
Trial details
- Registry ID
- NCT07161999
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as LD rhIL-2 and CTLA-4 Ig
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of COYA 302 for the Treatment of ALSNCT07161999 | Coya Therapeutics | Phase 2, Phase 3 | Active not recruiting | 2027-04Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |